Travere Therapeutics (NASDAQ:TVTX) Insider William Rote Sells 96,198 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider William Rote sold 96,198 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $62.25, for a total transaction of $5,988,325.50. Following the sale, the insider directly owned 98,197 shares of the company’s stock, valued at $6,112,763.25. This represents a 49.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Up 2.0%

TVTX opened at $64.74 on Friday. The company has a market cap of $6.10 billion, a PE ratio of -140.74 and a beta of 1.05. Travere Therapeutics, Inc. has a twelve month low of $22.06 and a twelve month high of $68.73. The company has a 50-day moving average price of $61.63 and a 200 day moving average price of $48.50. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The company had revenue of $169.58 million for the quarter, compared to analysts’ expectations of $157.27 million. During the same period in the previous year, the firm posted $0.13 EPS. Travere Therapeutics’s revenue was up 48.2% compared to the same quarter last year. Sell-side analysts expect that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current fiscal year.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

Analysts Set New Price Targets

TVTX has been the subject of several research reports. TD Cowen boosted their price target on Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Wedbush lifted their target price on shares of Travere Therapeutics from $61.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Canaccord Genuity Group upped their target price on shares of Travere Therapeutics from $62.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings cut shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Finally, Wells Fargo & Company raised their price target on shares of Travere Therapeutics from $50.00 to $65.00 and gave the stock an “overweight” rating in a research note on Friday, June 12th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $68.00.

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its stake in Travere Therapeutics by 53.4% during the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after buying an additional 211 shares during the last quarter. Fifth Third Bancorp acquired a new stake in shares of Travere Therapeutics in the 1st quarter worth $35,000. Allworth Financial LP acquired a new stake in shares of Travere Therapeutics in the 2nd quarter worth $47,000. Integrated Wealth Concepts LLC purchased a new position in shares of Travere Therapeutics during the 2nd quarter worth $70,000. Finally, IFP Advisors Inc raised its holdings in shares of Travere Therapeutics by 11,770.0% during the 4th quarter. IFP Advisors Inc now owns 2,374 shares of the company’s stock worth $91,000 after acquiring an additional 2,354 shares during the period.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.